Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Carlsmed, Inc.
CARL
NASDAQ·Healthcare·Information Technology Services·Mkt cap $318.3M
$11.34
▼ -3.16%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$8.50 - $17.19
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 19.2% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary AI and image recognition technology for surgical planning
- Integrated 3D printing capabilities for personalized device manufacturing
- CMS NTAP reimbursement approval reducing market adoption barriers
- Specialized focus on complex adult spinal deformities with high clinical need
Bear Case
2 risks
- Above-average volatility (beta 2.0).
- Growth premium of 0.0x vs Healthcare IT & Services peers. Reasonable for this growth rate.
Growth
Strong growth ahead
Expanding adoption of personalized medicine and precision surgery in orthopedics
Value
Growth premium of 0.0x vs Healthcare IT & Services peers. Reasonable for this growth rate.
Momentum
Hot
+20.4% over 3m
Quality
Excellent
Emerging growth company (75% revenue growth). Early stage with higher risk.
Dividend
None
No dividend
Smart-money signal
Who's buying CARL right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Apr 30, 2026
MAY 5, 2026
Reported EPS of -$0.32 vs -$0.43 consensus (+25.6% surprise). Revenue of $16.1M vs $14.9M expected (+7.8%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+25.6%
Next: Apr 30, 2026
Revenue trend · last 8Q
—
—
+117%
+100%
+99%
+98%
+61%
+58%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$6.1M
$6.6M
$9.4M
$10.2M
$12.1M
$13.1M
$15.2M
$16.1M
Margins · last 8Q
Gross
—
Operating
—
Profit
-54.0%
Wall Street consensus
3 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
$18.00
▲ +58.7% vs $11.34
Latest: BTIG · May 6, 2026
1 analyst covering